Proprotein Convertase Subtilisin-Kexin Type 9 inhibitors and stroke prevention: A meta-analysis.

In conclusion, the present systematic review and meta-analysis showed that in patients with previous cardiovascular events, the risk of stroke was significantly reduced in patients with and without previous stroke treated with PCSK9 inhibitors irrespective of the baseline LDL-C levels. Keywords: Lipid-lowering; Statin; PCSK9 inhibitor; Evolocumab; Alirocumab; Stroke EN Lipid-lowering Statin PCSK9 inhibitor Evolocumab Alirocumab Stroke 130 132 3 03/03/21 20210301 NES 210301 Dear Editor, over the last decades lipid-modifying strategies made a pivotal change in cardiovascular prevention especially in patients with previous coronary artery disease or ischemic stroke. The beneficial effect of PCSK9 inhibitors in patients with previous cardiovascular events and stroke was not related to an increase of hemorrhagic stroke rates, irrespectively of the LDL-C levels. [Extracted from the article]